- PR Newswire•yesterdayFDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris
SAN DIEGO, Jan. 18, 2017 /PRNewswire/ -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that its product candidate Resolaris™ was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of limb girdle muscular dystrophy 2B (LGMD2B), making it the first known therapeutic candidate for the treatment of LGMD2B to receive the designation. In addition, the FDA removed its partial clinical hold on a dosing ceiling for Resolaris in clinical trials.
- Associated Press•15 days ago
Supreme Court Chief Justice John Roberts says he will no longer participate in deciding a patent infringement case because he discovered he owns shares in the parent company of one of the parties. Roberts ...
- GuruFocus.com•29 days ago
CEO and Director of Atyr Pharma Inc (NASDAQ:LIFE) John Mendlein bought 69,000 shares of LIFE on 12/19/2016 at an average price of $2.2 a share.
LIFE : Summary for aTyr Pharma, Inc. - Yahoo Finance
aTyr Pharma, Inc. (LIFE)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||3.05 x 400|
|Ask||3.10 x 1400|
|Day's Range||3.00 - 3.10|
|52 Week Range||2.10 - 6.81|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.22|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|